眼筋型重症筋無力症の再燃なくペムブロリズマブによる治療が可能であった転移性尿管癌の1例

DOI HANDLE Web Site オープンアクセス
  • 原 修平
    東京慈恵会医科大学葛飾医療センター泌尿器科
  • 本田 真理子
    東京慈恵会医科大学葛飾医療センター泌尿器科
  • 川原田 綺香
    東京慈恵会医科大学泌尿器科
  • 中薗 実
    東京慈恵会医科大学葛飾医療センター泌尿器科
  • 大沼 源
    東京慈恵会医科大学葛飾医療センター泌尿器科
  • 山田 裕紀
    東京慈恵会医科大学葛飾医療センター泌尿器科
  • 清田 浩
    東京慈恵会医科大学葛飾医療センター泌尿器科
  • 頴川 晋
    東京慈恵会医科大学泌尿器科

書誌事項

タイトル別名
  • A Case of Metastatic Ureteral Cancer Treated with Pembrolizumab without Relapse of Ocular Myasthenia Gravis
  • ガンキンガタ ジュウショウ キンムリョクショウ ノ サイネン ナク ペムブロリズマブ ニ ヨル チリョウ ガ カノウ デ アッタ テンイセイ ニョウカンガン ノ 1レイ

この論文をさがす

説明

A 77-year-old man complaining of gross hematuria was referred to our hospital for further examination and treatment. The contrast-enhanced computed tomographic (CT) scan revealed a left ureteral tumor, multiple bladder tumors, para-aortic lymph node metastasis, left supraclavicular lymph node metastasis, multiple liver metastases, and multiple lung metastases. Transurethral resection was performed. One of the multiple bladder tumors, located at the bladder neck, was pathologically diagnosed as urothelial carcinoma, pT1, high grade, G2．We diagnosed the patient with metastatic ureteral cancer (T4N2M1, stage IV). We stated gemcitabine, cisplatin (GC) therapy, but stopped after the first course due to gemcitabine drug eruption. We changed the regimen to methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) therapy and the cycle was completed without complications. However, CT scan showed disease progression. After palliative irradiation of the primary lesion, we administered pembrolizumab. Although he was asymptomatic, we diagnosed him with ocular myasthenia gravis because of a high level of serum anti-acetylcholine receptor antibodies and a temporary ptosis in his past history. In spite of the possibility of relapse of myasthenia gravis, treatment with pembrolizumab was continued with his consent since there were no other treatment options. After two courses of pembrolizumab, he was hospitalized due to disease progression and died about three weeks after admission. Myasthenia gravis is a possible immune-related adverse event of pembrolizumab, However, there have been few reports on the successful treatment with this agent in patients with previously diagnosed myasthenia gravis. We report, here, a case of metastatic ureteral carcinoma safely treated with pembrolizumab without relapse of ocular myasthenia gravis.

収録刊行物

  • 泌尿器科紀要

    泌尿器科紀要 68 (12), 377-383, 2022-12-31

    泌尿器科紀要刊行会

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ